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Introduction
Sjögren Syndrome (SS) is a systemic autoimmune disease 
that mainly affects the exocrine glands and usually presents 
as persistent dryness of the mouth and eyes due to functional 
impairment of the salivary and lachrymal glands [1]. 
Nearly one third of patients may present inflammatory, 
episodic swelling of the major salivary glands (parotid and 
submandibular glands) and, less frequently, swelling of 
the lachrymal glands. The disease overwhelmingly affects 
middle-aged women, but may also affect children, men and 
the elderly. The histological hallmark is focal lymphocytic 
infiltration of the exocrine glands, and the spectrum of the 
disease extends from an organ-specific autoimmune disease 
(autoimmune exocrinopathy) [2] to a systemic process with 
diverse extraglandular manifestations [3,4]. 
Xerostomia (subjective feeling of mouth dryness) is one 
of the key symptoms in the suspicion of SS, as it occurs in 
more than 95% of patients; a positive answer to at least one of 
the three questions about oral symptoms included in the 2002 
classification criteria has a positive and negative predictive 
value of 54-77% and 94-98%, respectively [5]. Reduced 
salivary volume interferes with speaking or eating and may 
facilitate local infection and tooth decay, with a lobulated/
depapillated red tongue and angular cheilitis being the most 
frequent oral signs.
Primary SS patients have poor health-related quality 
of life (HRQOL), which is comparable to that observed in 
patients with fibromyalgia or chronic pain [6]. Some studies 
[7] have found that oral disease may have significant social 
and psychological consequences and contribute to impaired 
general quality of life in these patients. Patients complain of 
difficulties in chewing, swallowing food and speaking [8], 
and consequently may suffer embarrassment or feel self-
conscious socially as a result of xerostomia [7]. However, the 
great majority of studies focused on HRQOL in primary SS 
have found that a specific cluster of symptoms (fatigue, pain, 
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Objective: To evaluate health-related quality of life in a large series of primary SS patients using the recently-proposed ESSPRI 
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Results: Mean intensity of oral dryness measured by the corresponding ESSPRI item was 7.17 ± 0.23. Oral dryness correlated 
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a statistically-significant trend for anxiety and depression measured by the HADS (p=0.08 and 0.07, respectively). No significant 
correlation was found with the main extraglandular and immunological features; however, a significant correlation between oral 
dryness and hypertension (p=0.019), type II diabetes mellitus (p=0.005) and hypercholesterolemia (p=0.011) was found. Multivariate 
regression analysis shows that fatigue measured by ESSPRI (p=0.049), sleep quality (p=0.008) and hypercholesterolemia (p=0.008) 
were independently associated with dry mouth.
Conclusion: We report on the usefulness of the ESSPRI index in evaluating HRQOL associated with oral dryness in primary SS 
patients. Oral dryness correlated with age and the other sicca symptoms measured by ESSPRI, but not with the main systemic 
and immunological SS features. In contrast, oral dryness was strongly correlated with fatigue, pain, psychological distress, poor 
sleep and vascular risk factors. A multidisciplinary therapeutic approach may be the best way of minimizing oral dryness and its 
consequences in primary SS patients.
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sleep disturbances and emotional distress) are the principle 
reason for poor HRQOL, together with sicca features [9]. It 
is not clear how the coexistence of these non-specific general 
features and other SS-related features may influence the 
intensity of oral dryness.
The aims of this study were to evaluate HRQOL in a large 
series of primary SS patients using the recently-proposed 
ESSPRI questionnaire and to evaluate the relationship 
between the intensity of oral dryness and other signs and 
symptoms frequently found in these patients (general 
symptoms, autoimmune features and vascular risk factors).
Patients and Methods
Between January and December 2011, we evaluated 90 
primary SS patients seen consecutively in the outpatient 
clinic of the Department of Autoimmune Diseases (Hospital 
Clínic, Barcelona). All patients were considered to have 
well-established primary SS after fulfillment of the current 
classification criteria, either the AECD criteria [5] or the 
ACR criteria [10], including either positive autoantibodies 
or salivary biopsy as a mandatory criterion. In all patients, 
an exhaustive evaluation discarding other causes of sicca 
syndrome (coexisting systemic autoimmune diseases, chronic 
viral infections, and pre-existing lymphoma) was made. 
Clinical and laboratory data were collected and computerized 
according to our standard department protocol [4]. The study 
was approved by the Ethics Committee of the Hospital Clinic 
(Barcelona, Spain) and all patients gave informed, written 
consent.
All patients completed the ESSPRI questionnaire (mean 
score of 0–10 numerical scales for pain, fatigue, and dryness 
features, including oral, ocular, and global dryness) [11]. The 
intensity of oral dryness was measured using the corresponding 
ESSPRI item, which uses a 1 0-cm visual analogue scale 
(VAS) with the anchor points being ‘No dry mouth’ and 
‘Worst possible dry mouth’. We compared the mean values of 
the ESSPRI-dry mouth item with the following SS features:
- Other ESSPRI items related to sicca features other than 
dry mouth (VAS for dry eyes, dry nasopharynx, cutaneous 
and vaginal dryness)
- General symptoms: fatigue and pain using the 
corresponding ESSPRI items, and the Brief Pain Inventory 
(BPI) questionnaire
- HRQOL: 0-10 patient global assessment (PGA), SF-36, 
HAQ and Fibromyalgia Impact Questionnaire (FIQ), VAS for 
quality of sleep
- Psychological and psychiatric features: Hospital 
Anxiety and Depression Scale (HADS) and General Health 
Questionnaire (GH28) 
- Extraglandular involvement was evaluated according to 
the 2010 EULAR SS disease activity index [12]. 
- Laboratory features and immunological markers (positive 
ANA, RF, anti-Ro/SS-A and anti-La/SS-B antibodies)
- Cardiovascular risk factors: The following data were 
retrospectively collected from the medical and analytical 
records of primary SS patients at the time of the visit: 
hypertension, current smoking, diabetes mellitus, obesity, 
hypercholesterolemia and hypertriglyceridemia [13].
Statistical Analysis
Descriptive data are presented as the mean and standard 
deviation (SD) for continuous variables or number and 
percentage (%) for categorical variables. Spearman correlation 
coefficients were computed to study the relation between dry 
mouth and other continuous variables and t-test to evaluate 
the association of dry mouth with categorical variables. 
Multivariate linear regression analysis with a backwards 
stepwise selection method was performed to identify those 
variables that were independently associated with dry mouth. 
All significance tests were 2-tailed and p-values<0.05 were 
considered significant. All analyses were conducted using 
statistical software package R version 3.0.2 for Windows.
Results
a) Baseline characterization
The baseline characteristics of the study group are summarized 
in Table 1. We included 90 patients, 86 (96%) females and 
4 (4%) males (female:male ratio, 21:1), with a mean age at 
diagnosis of 56.32 ± 1.47 years (range, 22-81), a mean age 
at study inclusion of 63.54 ± 1.48 years (range, 25-84) and 
a disease evolution ranging from 12 to 252 months (mean, 
7.45 years). All patients had xerostomia and xerophthalmia, 
81/89 (91%) had altered ocular diagnostic tests (Schirmer’s 
test and/or rose Bengal/lissamine stainings), 77/79 (97%) 
altered salivary scintigraphy and 20/31 (65%) a salivary gland 
biopsy showing lymphocytic infiltrates grade 3 or 4. The main 
immunologic features were ANA>1/80 in 81 (90%) patients, 
anti-Ro/SS-A in 40 (44%), RF in 39 (43%), anti-La/SS-B in 
32 (36%), low C3 levels in 6/88 (7%), low C4 levels in 2/88 
(2%) and cryoglobulinemia in 9/86 (11%)
b) Association between oral dryness, non-specific general 
features and HRQOL
Mean intensity of oral dryness measured by the corresponding 
ESSPRI item was 7.17 ± 0.23. Table 2 summarizes the 
correlation between oral dryness and the intensity of other 
sicca features measured according to the corresponding 
ESSPRI items; we found a close correlation between the 
intensity of oral dryness and the intensity of the other dryness 
features (p<0.001). With respect to general symptoms, oral 
dryness correlated with the intensity of fatigue, both mental 
Variables at diagnosis N=90
Gender (male) 4 (4)
Age (mean ± SD) 56.32 ± 1.47
Dry mouth 90 (100)
Dry eyes 90 (100)
Altered ocular tests 81/89 (91)
Altered salivary scintigraphy 77/79 (97)
Positive salivary gland biopsy 20/31 (65)
Antinuclear antibodies+ 81 (90)
Rheumatoid factor+ 39 (43)
Anti-Ro/SS-A+ 40 (44)
Anti-La/SS-B+ 32 (36)
Cryoglobulins+ 9/86 (11)
Low C3 levels (<0.82 g/L) 6/88 (7)
Low C4 levels (<0.11 g/L) 2/88 (2)
Table 1. Baseline characteristics of a Spanish cohort of 90 patients 
with primary SS.
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(p=0.001) and general (p=0.024), and with pain measured 
by the ESSPRI items (p=0.048), together with a statistically-
significant trend for pain measured with the BPI questionnaire 
(p=0.091).
Table 3 summarizes the correlation between the intensity 
of oral dryness and HRQOL. No significant correlation was 
found with SF-36 domains and dimensions except for a 
statistical trend for physical health (p=0.065). No correlation 
between the intensity of oral dryness and functional disability 
measured by the HAQ and FIQ questionnaires was found. 
However, we found a significant correlation between the 
intensity of oral dryness and the quality of sleep measured by 
the Quality of Sleep questionnaire (p=0.001). With respect to 
psychological and psychiatric features, we found a significant 
correlation between the intensity of oral dryness and anxiety 
and depression measured by the GH28 (p=0.004 and 0.024, 
respectively), and a statistically-significant trend for anxiety 
and depression measured by the HADS (p=0.08 and 0.07, 
respectively),
c) Association between oral dryness and SS-related 
features
Table 4 summarizes the correlation between the intensity 
of oral dryness and the main epidemiological, clinical and 
immunological features of primary SS patients. Oral dryness 
correlated with age both at diagnosis and at study inclusion 
(p=0.013), but not with gender or with time of disease 
evolution. No significant correlation was found with the main 
extraglandular and immunological features.
d) Association between oral dryness and vascular risk 
factors
Table 5 summarizes the correlation between the intensity 
of oral dryness and the main vascular risk factors. There 
was a significant correlation between oral dryness and 
hypertension (p=0.019), type II diabetes mellitus (p=0.005) 
and hypercholesterolemia (p=0.011).
Correlation Coefficient P-value
Other dryness
ESSPRI dryness eyes 0.57 <0.001
ESSPRI dryness skin 0.41 <0.001
ESSPRI dryness nose 0.41 <0.001
ESSPRI tracheal dryness 0.50 <0.001
ESSPRI vaginal dryness 0.45 <0.001
Fatigue
ESSPRI global fatigue 0.24 0.024
ESPPRI mental fatigue 0.36 0.001
Pain
ESSPRI pain 0.21 0.048
BPI total score 0.18 0.091
Table 2. Correlation between the intensity of oral dryness and 
the intensity of other sicca features, fatigue and pain measured 
according to the corresponding ESSPRI items.
Correlation Coefficient P-value
SF-36 dimensions
SF36 health -0.15 0.172
SF36 physical function -0.14 0.208
SF36 physical role -0.07 0.523
SF36 pain -0.09 0.422
SF36 emotional role -0.16 0.140
SF36 social function -0.10 0.338
SF36 vitality -0.09 0.417
SF36 mental health 0.07 0.496
SF36 physical heath sum -0.20 0.065
SF36 mental health sum -0.10 0.377
PGA score 0.08 0.438
Quality of sleep 0.33 0.002
HAQ total score 0.17 0.117
FIQ total score 0.13 0.269
HADS anxiety score 0.19 0.080
HADS depression score 0.19 0.070
GH28 psychosomatic 0.04 0.705
GH28 anxiety 0.30 0.004
GH28 social dysfunction 0.04 0.692
GH28 depression 0.24 0.024
Table 3. Correlation between oral dryness intensity and HRQOL 
questionnaires.
Correlation Coefficient P-value
Age at diagnosis 0.26 0.017
Age at study inclusion 0.23 0.034
Time of disease evolution -0.02 0.893
Absence Presence P-value
Gender 6.8 ± 2.5♂ 7.2 ± 2.2♀ 0.752
Parotid enlargement 7.2 ± 2.4 7.2 ± 1.6 0.931
Arthralgia 7.4 ± 2.1 7.0 ± 2.3 0.310
Arthritis 7.1 ± 2.2 7.5 ± 2.3 0.670
Vasculitis 7.2 ± 2.2 6.7 ± 1.2 0.525
Pulmonary involvement 7.1 ± 2.3 7.4 ± 1.9 0.628
Renal involvement 7.2 ± 2.2 7.3 ± 2.3 0.911
Peripheral neuropathy 7.2 ± 2.1 5.3 ± 4.5 0.542
CNS involvement 7.2 ± 2.2 7.1 ± 2.2 0.828
Antinuclear antibodies+ 7.9 ± 0.8 7.1 ± 2.3 0.060
Rheumatoid factor+ 7.2 ± 2.4 7.2 ± 2.0 0.955
Anti-Ro/SS-A+ 7.4 ± 2.1 6.8 ± 2.4 0.228
Anti-La/SS-B+ 7.1 ± 2.5 7.4 ± 1.6 0.461
Low C3 levels (<0.82 g/L) 6.2 ± 2.9† 7.2 ± 2.2¶ 0.419
Low C4 levels (<0.11 g/L) 7.5 ± 2.1† 7.2 ± 2.2¶ 0.855
Cryoglobulins+ 7.2 ± 2.2‡ 6.6 ± 2.3χ 0.412
Monoclonal band+ 7.2 ± 2.3‡ 6.1 ± 1.9χ 0.077
†Reduced; ¶Normal; ‡Negative; χPositive; ♂Male; ♀Female
Table 4. Correlation between the intensity of oral dryness (mean 
± SD) and the main epidemiological, clinical and immunological 
features of primary SS.
Absence Presence P-value
Vascular risk factors 6.5 ± 2.7 7.3 ± 2.1 0.368
Smoker 7.3 ± 2.0 6.6 ± 2.8 0.332
Hypertension 6.8 ± 2.3 7.9 ± 1.9 0.019
Type II diabetes 6.8 ± 2.3 8.1 ± 1.6 0.005
Hypercholesterolemia 6.6 ± 2.3 7.8 ± 1.9 0.011
Hypertriglyceridemia 7.0 ± 2.2 7.6 ± 2.1 0.309
Obesity 7.0 ± 2.4 7.1 ± 1.3 0.859
Hyperuricemia 7.1 ± 2.2 7.8 ± 1.9 0.490
Metabolic syndrome 7.1 ± 2.3 7.9 ± 1.8 0.207
Table 5. Correlation between oral dryness intensity (mean ± SD) 
and the main vascular risk factors of patients with primary SS.
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e) Multivariate model
The multivariate regression model analysed independent 
variables associated with dry mouth; dryness of other 
mucosal surfaces was excluded due to the evident correlation. 
Variables with a p-value<0.05 in the univariate analysis 
(fatigue measured by ESSPRI, pain measured by ESSPRI, 
anxiety and depression measured by GH28, age, quality of 
sleep, hypertension, diabetes and hypercholesterolemia) 
were included in the model. Table 6 summarizes the main 
results: multivariate regression analysis shows that fatigue 
measured by ESSPRI (p=0.049), sleep quality (p=0.008) 
and hypercholesterolemia (p=0.008) were independently 
associated with dry mouth.
Discussion
As in other systemic diseases, measurement of HRQOL in 
primary SS is an important but complex issue [9]. Several 
factors may contribute to impaired HRQOL in SS, including 
dryness, non-specific general symptoms (chronic pain, physical 
and mental fatigue) and emotional distress [14]. The lack of 
disease-specific HRQOL questionnaires meant that the first 
studies carried out in primary SS patients used non-specific 
disease questionnaires, mainly the SF-36 questionnaire; 
these studies found that all components of HRQOL were 
clearly altered in SS in comparison with control groups 
[15,16]. Disease-specific indexes were developed for specific 
evaluation of symptoms (subjective features) in SS patients, 
including the Profile of Fatigue and Discomfort (PROFAD), 
the Sicca Symptoms Inventory (SSI) [17,18], and the SS 
Disease Activity Index (SSDAI) for systemic features [19]. 
Based on the results of these studies, the EULAR has recently 
promoted an international collaboration between SS experts 
to develop consensus disease activity indexes. Two indexes 
have been developed, the EULAR Sjögren’s Syndrome 
Disease Activity (ESSDAI) for systemic involvement [12], 
and the EULAR Sjögren’s Syndrome Patient Reported 
Index (ESSPRI), which is based on a patient-administered 
questionnaire that evaluates subjective symptoms [11]. The 
ESSPRI index domains were selected according to data from 
the development of the SSI and PROFAD. The selection of 
domains and determination of their weighting was determined 
from the patients’ perspective, using a multiple linear 
regression model, where patient global assessment was the 
gold standard. The ESSPRI uses a 0 to 10 numerical scale, 
with a scale for the assessment of each of the 3 domains: 
dryness, fatigue and pain (joint and/or muscular) [20]. The 
ESSPRI index is an independent determinant of HRQOL in 
primary SS patients in comparison with non-Sjogren's sicca 
patients [21].
Our study evaluated how the intensity of oral dryness 
(using the corresponding ESSPRI item) may be influenced 
by other features frequently reported by primary SS patients, 
including not only other sicca features, but also general 
symptoms, systemic features and vascular risk factors. The 
intensity of oral dryness correlated closely with the intensity 
of other forms of dryness, with our results confirming a finding 
commonly reported by SS patients: the greater the intensity 
of dry mouth, the greater the intensity of other forms of 
dryness. The finding of a correlation between the intensity of 
dry mouth and age might also have been expected. However, 
we found no correlation with the main systemic features and 
immunological markers of primary SS, confirming that the 
association between sicca and systemic symptoms is weak. 
Studies have shown that ESSDAI (systemic, objective activity) 
and ESSPRI (subjective symptoms) are not necessarily 
correlated [20,22], suggesting that patients’ symptoms and 
systemic complications are two different components of the 
disease that should be evaluated separately; however, these 
studies have also showed that ESSPRI is valid to be used as a 
tool to monitor therapeutic response [23].
With respect to HRQOL, we found a slight correlation 
between the intensity of oral symptoms and the main non-
specific disease questionnaires (SF-36, HAQ, FIQ). Although 
there was a statistical trend for the majority of items and 
dimensions, no significant differences were found, suggesting 
that oral dryness influences general HRQOL, but, in itself, 
not strongly. Our results differ from those of Enger et al. 
[24] who found that patients with high levels of oral distress 
(measured by the Oral Health Impact Profile 14, OHIP-14) 
scored significantly worse than patients with low levels of oral 
distress in five of the SF-36 subscales. However, the variable 
used in this study (oral distress) is different from that used in 
our study, and therefore the results are not comparable with 
ours. Other studies have found a poor correlation between the 
intensity of oral symptoms and HRQOL [25,26].
Most studies have found that non-specific general 
complaints are the key factors that contribute to worse HRQOL 
in primary SS patients. Abnormal fatigue is a frequent reason 
for consultation, with a prevalence in SS of>80% and with 
a close association with work disability [27,28], together 
with chronic pain, which is reported by more than 50% of 
patients. Other non-specific symptoms closely associated 
with fatigue and pain are sleep disturbances, anxiety, and 
depression, with prevalence according to recent studies of 
nearly 15%, 20% and 40%, respectively [28-30]. A recent 
study by Lendrem et al. [31] found that pain and depression 
were the two most important predictors of HRQOL (using 
the EQ-5D questionnaire) using a multiple regression model 
adjusted for age and gender. Pain and depression accounted 
for 48% of the HRQOL variability, with anxiety and fatigue 
being other statistically significant predictors, accounting 
for<5%. Another recent study found that primary SS patients 
had higher fatigue levels and also suffered from excessive day 
time sleepiness. Fatigue, sleepiness, anxiety and depressive 
Estimate Std. Error t value P-value
(Intercept) 4.56 0.53 8.58 <0.001
ESPPRIfatgmen 0.15 0.08 2.00 0.049
ECS 0.21 0.08 2.71 0.008
HCOL 1.18 0.43 2.73 0.008
Table 6. Multivariate linear regression analysis with a backwards stepwise selection method of variables associated with intensity of dry mouth.
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symptoms, and sleep onset latency were significantly greater 
in primary SS patients than in controls [32].
Our results show a close association between the intensity 
of oral dryness and the main non-specific general complaints, 
including chronic pain, depression, anxiety and, especially, 
fatigue. Fatigue is a major predictor of worse HRQOL in 
primary SS [14,15,33]. In addition, Fox et al. [34] found 
that oral sicca severity (measured by the PROFAD-SSI 
questionnaire) was associated with lower energy levels and 
greater fatigue levels. It is unclear how fatigue could increase 
the intensity of oral dryness. Fatigue has been linked with 
poor sleep and discomfort, including joint pain and sicca 
symptoms [32]; therefore it may be hypothesized that a 
constellation of different non-specific general symptoms 
which are closely interrelated (pain, psychological distress, 
fatigue and poor sleep) might be the key factors involved in 
the subjective feeling of severe oral dryness in primary SS 
patients. However, other factors not evaluated in our study 
(menopause, thyroid disease, drugs with anticholinergic 
effects) may have also influenced oral dryness intensity.
Interestingly, we found a significant correlation between 
the intensity of oral dryness and the key vascular risk factors 
(hypertension, diabetes and hypercholesterolemia); these 
patients had more severe oral dryness than patients without 
these risk factors. Improving sicca features by strict control 
of coexisting metabolic alterations is an attractive possibility 
and has been suggested in murine models of SS [35]. Some 
pharmacological agents used in patients with metabolic 
alterations might have a potential role as future treatments 
in primary SS, including thiazolidinediones, metformin, 
antioxidants and statins [36]. Likewise, the hypothesis that 
the worse the control of vascular risk factors, the worse the 
intensity of oral dryness, is of interest and opens a pathway to 
the evaluation of metabolic therapeutic interventions targeted 
towards improving oral dryness and, globally, improving oral 
health.
In summary, we report on the usefulness of the ESSPRI 
index in evaluating HRQOL associated with oral dryness in 
primary SS patients. Oral dryness correlated with age and the 
other sicca symptoms measured by ESSPRI, but not with the 
main systemic and immunological SS features. In contrast, 
oral dryness was strongly correlated with non-specific 
general symptoms (fatigue, pain, psychological distress and 
poor sleep) and vascular risk factors. A multidisciplinary 
therapeutic approach including specific measures targeting 
general symptoms, strict control of cardiovascular disease 
risk factors and specific oral management by the dental team, 
based on individualized treatment plans that address the 
severity of salivary dysfunction [7], may, at present, be the 
best way of minimizing oral dryness and its consequences in 
primary SS patients.
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